There is emerging evidence for the efficacy of monoclonal antibody (mAb) treatment for early COVID disease. Both Lilly and Regeneron have conducted randomized control trials to test this intervention. Based on the initial results of these trials, the FDA gave an EUA for both treatments with a set of inclusion criteria to focus the treatment on high-risk individuals.
The mAb treatment is given in the outpatient setting only by infusion. A typical protocol calls for a 1 hour infusion and a 1 hour post-infusion observation period.
HHS maintains a public site to which lists infusion points of care.